In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine

After tumour cell vaccination, tumour cells were found to be exclusively inside the spleen if the injection had been set directly into the spleen. The location of immunisation is a factor influencing the efficiency of tumour cell vaccination.

The research team from the Charité in Berlin showed before how gene-modified vaccines delivered directly inside the spleen provoked antigen cross-presentation by splenic antigen-presenting cells (not B-cells).

In their recent study Sophie Cayeux and her team analysed the way in which splenic CD11c+ cells and antigen-specific CD4+ T-cells interact. The scientists used tumour cells expressing ovalbumin. In this condition CD4+ T-cells are needed to induce a cytotoxic response of T-lymphocytes. By using bioluminescence imaging of luciferase expressing EL4-ovalbumin cells the team could proof that after splenic injection tumour cells are exclusively situated in the spleen.

Adoptively in vivo transferred 5,6- carboxy-succinimidyl-fluorescein-ester-labelled transgenic CD4+KJI-26+ cells that were specific for the class II OVA323-339 peptide proliferated in the spleen. The cells were only transiently activated and produced Interleukin-10 and Interleukin-4 and not IFN-γ.

Splenic CD11c+ cells are able to reduce CD4+ T-cell responses specific for the spleen. In doing so the antitumour systemic immunity is weakened.

Related antibodies on antibodies-online.com:

CD11c

Ovalbumin

CD4+ T-cells

Luciferase

Interleukin-10 (IL-10)

Interleukin-4 (IL-4)

Interferon-γ (IFN-γ)

Antibodies for the research area immunology: »Show antibodies

Antibodies for the research area oncology: »Show antibodies